Ali Tafreshi
Impact in
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- CAR-T cell therapy research
- Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 34
- Cancer Immunotherapy and Biomarkers 28
- PARP inhibition in cancer therapy 9
- Lung Cancer Research Studies 5
-
- Lung Cancer Treatments and Mutations 12
- Prostate Cancer Treatment and Research 10
- Lung Cancer Diagnosis and Treatment 7
- Co-authors
- Andrew Robinson (16 shared papers)Delvys Rodríguez‐Abreu (14 shared papers)Rina Hui (13 shared papers)Tibor Csőszi (12 shared papers)Sinéad Cuffe (12 shared papers)Maya Gottfried (12 shared papers)Nir Peled (12 shared papers)Katsuyuki Hotta (12 shared papers)
- Journals
- Journal of Clinical Oncology (11 papers)Annals of Oncology (10 papers)Journal of Thoracic Oncology (8 papers)Investigative Ophthalmology & Visual Science (6 papers)American Journal of Ophthalmology (5 papers)
- Partner nations
- United StatesAustraliaSpain
In The Last Decade
Ali Tafreshi
92 papers receiving 11.9k citations
Ali Tafreshi's Hit Papers
Peers
Comparison fields: 5 of 131
- Oncology 7.3k
- Pulmonary and Respiratory Medicine 3.8k
- Immunology 1.6k
- Ophthalmology 596
- Cancer Research 837
Countries citing papers authored by Ali Tafreshi
This map shows the geographic impact of Ali Tafreshi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ali Tafreshi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ali Tafreshi more than expected).
Fields of papers citing papers by Ali Tafreshi
This network shows the impact of papers produced by Ali Tafreshi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ali Tafreshi. The network helps show where Ali Tafreshi may publish in the future.
Co-authors
The 25 scholars most cited alongside Ali Tafreshi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 95 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer Hit paper breakdown → | 2016 | 7183 |
| 2 | Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater Hit paper breakdown → | 2019 | 1144 |
| 3 | Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% Hit paper breakdown → | 2021 | 654 |
| 4 | A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407 Hit paper breakdown → | 2020 | 421 |
| 5 | Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study Hit paper breakdown → | 2023 | 274 |
| 6 | 2017 | 257 | |
| 7 | 2012 | 142 | |
| 8 | 2021 | 132 | |
| 9 | 2006 | 128 | |
| 10 | 2012 | 102 | |
| 11 | 2010 | 99 | |
| 12 | 2018 | 87 | |
| 13 | 2018 | 84 | |
| 14 | 2011 | 69 | |
| 15 | 2012 | 66 | |
| 16 | 2020 | 62 | |
| 17 | 2017 | 58 | |
| 18 | 2019 | 57 | |
| 19 | 2022 | 46 | |
| 20 | 2011 | 46 |
About Ali Tafreshi
Ali Tafreshi is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Ophthalmology and Neurology, having authored 95 papers that have together received 12.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (28 papers), Glaucoma and retinal disorders (12 papers), Lung Cancer Treatments and Mutations (12 papers), Prostate Cancer Treatment and Research (10 papers), PARP inhibition in cancer therapy (9 papers), Lung Cancer Diagnosis and Treatment (7 papers), Bladder and Urothelial Cancer Treatments (5 papers) and Lung Cancer Research Studies (5 papers). The work is most often cited by research in Oncology (7.3k citations), Pulmonary and Respiratory Medicine (3.8k citations), Immunology (1.6k citations), Ophthalmology (596 citations) and Cancer Research (837 citations). Ali Tafreshi has collaborated with scholars based in United States, Australia and Spain. Frequent co-authors include Andrew Robinson, Delvys Rodríguez‐Abreu, Rina Hui, Tibor Csőszi, Sinéad Cuffe, Maya Gottfried, Nir Peled, Katsuyuki Hotta, Suman Rao and Julie R. Brahmer. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Investigative Ophthalmology & Visual Science and American Journal of Ophthalmology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.